3-sucCA
Based on 1 Customer Validation
3-sucCA is an orally available bacterial bile acid that exerts anti-MASH effects by promoting the growth of Akkermansia muciniphila. By remodeling the intestinal microbiota and promoting the growth of Akkermansia, 3-sucCA can improve intestinal barrier damage and reduce chronic low-level inflammation, thereby alleviating the progression of metabolic dysfunction-associated steatohepatitis (MASH). 3-sucCA accelerates the synthesis of cell wall peptidoglycan and has in vivo efficacy in the mouse MAFL-MASH model. 3-sucCA levels are low in the MAFLD model and are mainly used in the study of MASH.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.75%
- CAS 番号: 94159-47-4
- 分子式: C28H44O8
- 分子量:508.64
-
保管条件:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Endogenous Metabolite アイソフォーム固有の製品をすべて表示
More
生物活性
3-sucCA (1 mM, 10 mM, 50 mM; 48 h) promotes the growth of Akkermansia muciniphila in a dose-dependent manner[1].
3-sucCA (20 μM; 3 days) is relatively stable when incubated with feces-derived in vitro communities, while glycocholic acid was degraded within 24 h[1].
3-sucCA (10 μM; 48 h) significantly promotes the growth of Akkermansia muciniphila and inhibited the growth of Clostridium sporogenes and Enterococcus hirae[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:97 different bacterial species
-
Concentration:10 μM
-
Incubation Time:48 hours
-
Result:Significantly increased the growth yield of Akkermansia muciniphila and showed inhibitory effects on Clostridium sporogenes and Enterococcus hirae.
3-sucCA (10 mg/kg; oral gavage; 3 times a week; 3 weeks) fails to improve liver injury and liver histological abnormalities in the MASH model of germ-free (GF) C57BL/6J mice induced by CDAA-HFD diet[1].
3-sucCA (10 mg/kg; oral gavage; 3 times a week; 3 weeks) significantly attenuates the alleviating effect of MASH in the MASH model of Tlr4-/- C57BL/10ScNJ mice induced by CDAA-HFD diet[1].
3-sucCA (10 mg/kg; oral gavage; single dose) has a bioavailability of 11.5% in the SPF C57BL/6J mouse model and is mainly distributed in the colon contents[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:SPF C57BL/6J mice (male, 8-week-old) with CDAA-HFD-induced MASH model[1]
-
Dosage:10 mg/kg
-
Administration:oral gavage, 3 times per week, 3 weeks
-
Result:Reduced the ratio of liver mass to body mass, plasma levels of ALT and AST, and hepatic triglyceride content.
Alleviated hepatic steatosis, inflammation, and fibrosis, as shown by H&E, oil red O, and Sirius red staining.
The relative mRNA expression of genes involved in hepatic lipid synthesis, pro-inflammatory cytokine production, and collagen synthesis was decreased.
化学情報
-
CAS 番号 94159-47-4
-
性状 Solid
-
分子量 508.64
-
分子式 C28H44O8
-
Color White to off-white
-
SMILES
O[C@H]1[C@@]2([H])[C@@]3([H])[C@@]([C@@](CC3)([H])[C@H](C)CCC(O)=O)([C@H](C[C@]2([H])[C@@]4([C@](C[C@@H](CC4)OC(CCC(O)=O)=O)([H])C1)C)O)C
-
別名
3-Succinylated cholic acid
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : 175 mg/mL (344.05 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Nie Q, et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway. Cell. 2024 May 23;187(11):2717-2734.e33. [Content Brief]
[2]. Chang S, et al. Succinate supplementation alleviates liver cancer by inhibiting the FN1/SQLE axis-mediated cholesterol biosynthesis. iScience. 2025 Jan 2;28(2):111731. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9660 mL | 9.8301 mL | 19.6603 mL | 49.1507 mL |
| 5 mM | 0.3932 mL | 1.9660 mL | 3.9321 mL | 9.8301 mL | |
| 10 mM | 0.1966 mL | 0.9830 mL | 1.9660 mL | 4.9151 mL | |
| 15 mM | 0.1311 mL | 0.6553 mL | 1.3107 mL | 3.2767 mL | |
| 20 mM | 0.0983 mL | 0.4915 mL | 0.9830 mL | 2.4575 mL | |
| 25 mM | 0.0786 mL | 0.3932 mL | 0.7864 mL | 1.9660 mL | |
| 30 mM | 0.0655 mL | 0.3277 mL | 0.6553 mL | 1.6384 mL | |
| 40 mM | 0.0492 mL | 0.2458 mL | 0.4915 mL | 1.2288 mL | |
| 50 mM | 0.0393 mL | 0.1966 mL | 0.3932 mL | 0.9830 mL | |
| 60 mM | 0.0328 mL | 0.1638 mL | 0.3277 mL | 0.8192 mL | |
| 80 mM | 0.0246 mL | 0.1229 mL | 0.2458 mL | 0.6144 mL | |
| 100 mM | 0.0197 mL | 0.0983 mL | 0.1966 mL | 0.4915 mL |